Next Life Medical08.15.16
Next Life Medical, a patient focused medical device company, has acquired Emergent Respiratory, known for its emergency CPAP product line—the Porto2Vent. The company’s patented positive pressure ventilation platform incorporates proprietary “on-demand” pressure-balanced patient valves, single-use breathing circuits, and a line of proprietary masks for use as an early intervention to treat all forms of dyspnea (difficulty breathing) including CHF (congestive heart failure).
Porto2Vent is an advanced respiratory device that provides CPAP (continuous positive airway pressure) and assists spontaneously breathing patients in prehospital and hospital emergency room environments. Emergent’s Porto2Vent improves patient outcomes by decreasing ICU admissions, decreasing exposure to infections, decreasing the risk of readmission cost due to infection exposure, and ultimately shortening hospital stays. In addition, CPAP therapy has proven successful with patients because it is non-invasive, easily adjustable, does not require sedation, and is comfortable for users. Moreover, CPAP offers significant economic benefits to patients, emergency medical providers, and hospitals by avoiding the potentially substantial healthcare costs of long-term treatment and potential re-admission cost.
Emergent Respiratory has been providing patients the standard in CPAP care for over 10 years. Many customers and patients refer to the Porto2Vent as the "yellow standard" in care as the product is known for its bright yellow presence.
“We are excited about our acquisition of Emergent Respiratory. Next Life Medical has a passion for helping both patients and care givers at the same time. We’ve been pleased to hear testimonies from care givers who endorse the ease of use of the Emergent proprietary products,” commented Next Life Medical CEO Chris Oleksy. “It has also been music to our ears when these same care givers tell us that their repeat patients say ‘give me that yellow thing.’”
“Having served in law enforcement and as a volunteer firefighter, I know how important it is to deliver treatment that is both helpful to the individual in need and is done so efficiently and effectively,” added Ryan Oleksy, Next Life Medical’s president.
Porto2Vent is an advanced respiratory device that provides CPAP (continuous positive airway pressure) and assists spontaneously breathing patients in prehospital and hospital emergency room environments. Emergent’s Porto2Vent improves patient outcomes by decreasing ICU admissions, decreasing exposure to infections, decreasing the risk of readmission cost due to infection exposure, and ultimately shortening hospital stays. In addition, CPAP therapy has proven successful with patients because it is non-invasive, easily adjustable, does not require sedation, and is comfortable for users. Moreover, CPAP offers significant economic benefits to patients, emergency medical providers, and hospitals by avoiding the potentially substantial healthcare costs of long-term treatment and potential re-admission cost.
Emergent Respiratory has been providing patients the standard in CPAP care for over 10 years. Many customers and patients refer to the Porto2Vent as the "yellow standard" in care as the product is known for its bright yellow presence.
“We are excited about our acquisition of Emergent Respiratory. Next Life Medical has a passion for helping both patients and care givers at the same time. We’ve been pleased to hear testimonies from care givers who endorse the ease of use of the Emergent proprietary products,” commented Next Life Medical CEO Chris Oleksy. “It has also been music to our ears when these same care givers tell us that their repeat patients say ‘give me that yellow thing.’”
“Having served in law enforcement and as a volunteer firefighter, I know how important it is to deliver treatment that is both helpful to the individual in need and is done so efficiently and effectively,” added Ryan Oleksy, Next Life Medical’s president.
